Real-world outcomes of elacestrant in ER+/HER2−, ESR1-mutant metastatic breast cancer

In this publication snapshot, Dr Seth Wander explores whether the benefits of elacestrant observed in the EMERALD trial are translating into clinical practice, drawing on findings from the Komodo–Foundation Medicine real-world analysis. 

Key topics include: 

• The evolving ER+/HER2− mBC treatment landscape and the impact of ESR1 mutations 
• Key findings from the pivotal EMERALD trial 
• Real-world outcomes with elacestrant from the Komodo–Foundation Medicine analysis and how they complement existing evidence 

Watch Dr Wander's video and download the accompanying infographic for more details from the publication.

Clinical takeaways

• Elacestrant demonstrated a durable benefit in real-world clinical practice, particularly in earlier lines and in patients with prolonged prior ET exposure 
• Despite coexisting ESR1 and PI3K pathway mutations, TTNT remained clinically meaningful, reinforcing the role of elacestrant in personalized ET sequencing strategies prior to ChT, ADC, or targeted combinations 
• Magnitude of benefit seems to be greater in patients with no prior exposure to fulvestrant, and in those with no prior exposure to chemotherapy 
• The results of this real-world study are consistent with those of the EMERALD trial subgroup analysis in patients with endocrine-sensitive tumors